• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures.腹膜假黏液瘤行减瘤手术及腹腔内化疗后的生活质量研究,包括再次手术。
Int J Surg Oncol. 2013;2013:461041. doi: 10.1155/2013/461041. Epub 2013 Jul 28.
2
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.阑尾来源的假性黏液瘤行细胞减灭术(CRS)和腹腔内热灌注化疗(HIPEC):单中心研究结果。
Updates Surg. 2020 Dec;72(4):1207-1212. doi: 10.1007/s13304-020-00788-5. Epub 2020 May 14.
3
Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study.腹腔热灌注化疗治疗假性黏液瘤腹膜后长期生活质量的前瞻性纵向研究:细胞减灭术
Ann Surg Oncol. 2018 Apr;25(4):965-973. doi: 10.1245/s10434-017-6326-0. Epub 2018 Jan 8.
4
Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.根治性细胞减灭术和腹腔内热灌注化疗治疗阑尾来源的假性黏液瘤腹膜假性黏液瘤的可行性。
Scand J Surg. 2013;102(3):145-51. doi: 10.1177/1457496913490463.
5
Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.减瘤手术联合术后早期腹腔内化疗治疗腹膜假黏液瘤后的生活质量:一项前瞻性研究
Dis Colon Rectum. 2008 Jun;51(6):868-74. doi: 10.1007/s10350-008-9223-6. Epub 2008 Feb 23.
6
Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk?细胞减灭术和腹腔热灌注化疗后患者的生活质量:值得冒险吗?
Ann Surg Oncol. 2013 Jan;20(1):226-32. doi: 10.1245/s10434-012-2579-9. Epub 2012 Aug 7.
7
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.细胞减灭术及腹腔内热灌注化疗治疗腹膜假黏液瘤:单中心经验
Indian J Gastroenterol. 2017 Nov;36(6):452-458. doi: 10.1007/s12664-017-0799-4. Epub 2017 Nov 29.
8
[Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei].[细胞减灭术(腹膜切除术)及腹腔内热灌注化疗:一种治疗腹膜假黏液瘤的创新且有效的方法]
Tumori. 2003 Jul-Aug;89(4 Suppl):54-5.
9
Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.采用细胞减灭术和腹腔内热灌注化疗(HIPEC)治疗腹膜假黏液瘤:单中心经验
Minerva Chir. 2013 Dec;68(6):569-77.
10
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.细胞减灭术和腹腔热灌注化疗治疗腹膜癌转移:丹麦经验。
Colorectal Dis. 2013 Jul;15(7):e365-72. doi: 10.1111/codi.12185.

引用本文的文献

1
New insights in the management of pseudomyxoma peritonei.腹膜假黏液瘤治疗的新见解
J Surg Oncol. 2024 Nov;130(6):1316-1325. doi: 10.1002/jso.27842. Epub 2024 Aug 29.
2
Scalloping of the Liver and Spleen on Preoperative CT-Scan of Pseudomyxoma Peritonei Patients: Impact on Prediction of Resectability, Grade, Morbidity and Survival.腹膜假黏液瘤患者术前CT扫描中肝脏和脾脏的扇贝样改变:对可切除性、分级、发病率和生存率预测的影响
Cancers (Basel). 2022 Sep 13;14(18):4434. doi: 10.3390/cancers14184434.
3
Cost-effectiveness of Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis.多次减瘤手术联合腹腔内热灌注化疗治疗腹膜转移癌的成本效果分析。
In Vivo. 2022 May-Jun;36(3):1527-1533. doi: 10.21873/invivo.12863.
4
ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method.ASO作者反思:使用一种新型统计方法估计欧洲腹膜假黏液瘤的患病率。
Ann Surg Oncol. 2020 Dec;27(Suppl 3):771-772. doi: 10.1245/s10434-020-08691-4. Epub 2020 Jun 3.
5
Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.影响阑尾肿瘤来源的假性黏液瘤经细胞减灭术和腹腔热灌注化疗后长期生存的因素。
BJS Open. 2019 Feb 19;3(3):376-386. doi: 10.1002/bjs5.50134. eCollection 2019 Jun.
6
Pseudomyxoma peritonei induced by low-grade appendiceal mucinous neoplasm accompanied by rectal cancer: a case report and literature review.低度阑尾黏液性肿瘤伴直肠癌所致腹膜假黏液瘤:1例报告及文献复习
BMC Surg. 2019 Apr 25;19(1):42. doi: 10.1186/s12893-019-0508-6.
7
Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer?姑息性细胞减灭术和腹腔内热灌注化疗:当前的临床实践还是误称?
J Gastrointest Oncol. 2016 Feb;7(1):112-21. doi: 10.3978/j.issn.2078-6891.2015.132.
8
Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.腹膜假黏液瘤中的分泌性黏蛋白:病理生理学意义及潜在治疗前景
Orphanet J Rare Dis. 2014 May 5;9:71. doi: 10.1186/1750-1172-9-71.

本文引用的文献

1
Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.147例接受减瘤手术及围手术期腹腔内化疗的腹膜表面恶性肿瘤患者的胃肠道并发症
Int J Surg Oncol. 2011;2011:468698. doi: 10.1155/2011/468698. Epub 2011 Oct 16.
2
Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin.结直肠来源腹膜癌继发腹腔热灌注化疗行细胞减灭术后的生存和生活质量。
Ann Surg Oncol. 2011 Dec;18(13):3673-9. doi: 10.1245/s10434-011-1793-1. Epub 2011 Jun 15.
3
Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.阑尾来源的假性黏液瘤腹膜间皮瘤综合征 456 例患者的手术结果、早期并发症和长期生存。
Dis Colon Rectum. 2011 Mar;54(3):293-9. doi: 10.1007/DCR.0b013e318202f026.
4
Pseudomyxoma peritonei.腹膜假黏液瘤。
World J Gastrointest Oncol. 2010 Jan 15;2(1):44-50. doi: 10.4251/wjgo.v2.i1.44.
5
Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.前瞻性纵向研究细胞减灭术和腹腔内化疗治疗腹膜假黏液瘤后的生活质量。
Eur J Surg Oncol. 2010 Dec;36(12):1156-61. doi: 10.1016/j.ejso.2010.09.004. Epub 2010 Sep 22.
6
Morbidity and mortality of 109 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC) performed at a community hospital.在社区医院进行的 109 例连续细胞减灭术加腹腔内热灌注化疗(HIPEC)的发病率和死亡率。
World J Surg. 2010 Jan;34(1):62-9. doi: 10.1007/s00268-009-0281-2.
7
Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.腹膜表面恶性肿瘤细胞减灭术及腹腔热灌注化疗后的生活质量
J Surg Oncol. 2009 Sep 15;100(4):317-20. doi: 10.1002/jso.21327.
8
Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.细胞减灭术联合腹腔热灌注化疗(HIPEC)治疗腹膜假黏液瘤:十二年经验的结果分析
In Vivo. 2009 Jul-Aug;23(4):639-44.
9
Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality.减瘤手术联合腹腔内热灌注化疗治疗腹膜癌病是否仍应被视为高风险手术?:一项关于发病率和死亡率的系统评价
Ann Surg. 2009 Jun;249(6):900-7. doi: 10.1097/SLA.0b013e3181a45d86.
10
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei).关于阑尾黏液性肿瘤伴腹膜播散(腹膜假黏液瘤)局部区域治疗的共识声明
J Surg Oncol. 2008 Sep 15;98(4):277-82. doi: 10.1002/jso.21054.

腹膜假黏液瘤行减瘤手术及腹腔内化疗后的生活质量研究,包括再次手术。

Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures.

作者信息

Kirby Rachel, Liauw Winston, Zhao Jing, Morris David

机构信息

Hepatobiliary and Surgical Oncology Unit, UNSW Department of Surgery, St. George Hospital, Sydney, NSW 2217, Australia.

出版信息

Int J Surg Oncol. 2013;2013:461041. doi: 10.1155/2013/461041. Epub 2013 Jul 28.

DOI:10.1155/2013/461041
PMID:23984057
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3745838/
Abstract

BACKGROUND

Our aim was to evaluate the quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. We also conducted an analysis of all patients who underwent CRS and HIPEC for pseudomyxoma peritonei from 1997 to 2012.

METHODS

We contacted 87 patients using the FACT C (version 4) quality of life questionnaire, and FACIT-TS-G (version 1) was also used.

RESULTS

A total of 63 patients (response rate 72%) were available for quality of life interview and analysis. The median time from surgery to questionnaire evaluation was 31 months (range 6-161 months). 62% were females with an average age of 54 years. 22% of the patients had over one cytoreductive surgical procedure. We analysed our patients postoperatively based on physical, functional, social, and emotional well being who reported favourable outcomes in all sections. Patients who had a single procedure had a significantly higher score (P = 0.016) in the additional concerns section of the questionnaire. The patients who had a single procedure had better gastrointestinal digestion in terms of bowel control, appetite, and food digestion and also body appearance scoring.

CONCLUSIONS

79% of the patients stated that they would undergo further cytoreductive surgery and that redo procedures do not result in a significantly worse quality of life.

摘要

背景

我们的目的是评估腹膜假黏液瘤行肿瘤细胞减灭术及腹腔内化疗后的生活质量。我们还对1997年至2012年期间接受腹膜假黏液瘤肿瘤细胞减灭术(CRS)和热灌注化疗(HIPEC)的所有患者进行了分析。

方法

我们使用FACT C(第4版)生活质量问卷联系了87名患者,同时也使用了FACIT - TS - G(第1版)。

结果

共有63名患者(应答率72%)可进行生活质量访谈和分析。从手术到问卷调查评估的中位时间为31个月(范围6 - 161个月)。62%为女性,平均年龄54岁。22%的患者接受过一次以上的肿瘤细胞减灭手术。我们根据身体、功能、社会和情感健康状况对患者术后情况进行了分析,所有方面均报告了良好结果。接受单次手术的患者在问卷的其他关注点部分得分显著更高(P = 0.016)。在肠道控制、食欲和食物消化以及身体外观评分方面,接受单次手术的患者胃肠消化功能更好。

结论

79%的患者表示他们愿意接受进一步的肿瘤细胞减灭手术,再次手术并不会导致生活质量显著下降。